Head to Head Analysis: Immuneering (NASDAQ:IMRX) vs. Entrada Therapeutics (NASDAQ:TRDA)

Immuneering (NASDAQ:IMRX) and Entrada Therapeutics (NASDAQ:TRDA) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, dividends, valuation and analyst recommendations.

Profitability

This table compares Immuneering and Entrada Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Immuneering	N/A	-31.93%	-29.92%
Entrada Therapeutics	-2,895.05%	-51.22%	-42.20%

Institutional & Insider Ownership

67.7% of Immuneering shares are held by institutional investors. Comparatively, 86.4% of Entrada Therapeutics shares are held by institutional investors. 22.9% of Immuneering shares are held by insiders. Comparatively, 9.5% of Entrada Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent recommendations for Immuneering and Entrada Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immuneering	1	0	4	1	2.83
Entrada Therapeutics	1	2	3	0	2.33

Immuneering currently has a consensus price target of $16.50, indicating a potential upside of 274.15%. Entrada Therapeutics has a consensus price target of $17.50, indicating a potential upside of 146.83%. Given Immuneering’s stronger consensus rating and higher probable upside, equities research analysts plainly believe Immuneering is more favorable than Entrada Therapeutics.

Volatility and Risk

Immuneering has a beta of 0.38, indicating that its share price is 62% less volatile than the S&P 500. Comparatively, Entrada Therapeutics has a beta of -0.26, indicating that its share price is 126% less volatile than the S&P 500.

Valuation and Earnings

This table compares Immuneering and Entrada Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immuneering	N/A	N/A	-$56.03 million	($1.17)	-3.77
Entrada Therapeutics	$5.74 million	47.97	-$143.75 million	($3.99)	-1.78

Immuneering has higher earnings, but lower revenue than Entrada Therapeutics. Immuneering is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Immuneering beats Entrada Therapeutics on 11 of the 14 factors compared between the two stocks.

About Immuneering

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.

About Entrada Therapeutics

Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.